Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1-overexpressing HeLa cells

References

• Ai L, Zhu L, Yang L, et al. (2014). Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica 44:320–5
   PubMed Web of Science ®Google Scholar
• Bjorkman IK, Fastborn J, Schmidt IK, Bernstein CB. (2002). Drug–drug interactions in the elderly. Ann Pharmacother 36:1675–81
   PubMed Web of Science ®Google Scholar
• Chang JH, Plise E, Cheong J, et al. (2013). Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067–75
   PubMed Web of Science ®Google Scholar
• Fisher MB, Campanale K, Ackermann BL, et al. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560–6
   PubMed Web of Science ®Google Scholar
• Fujita K, Sparreboom A. (2010). Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 5:209–17
   PubMedGoogle Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–15
   PubMed Web of Science ®Google Scholar
• Lipinski CA. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235–49
   PubMed Web of Science ®Google Scholar
• Liu H, Sun H, Lu D, et al. (2014a). Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence. Xenobiotica 44:696–707
   PubMed Web of Science ®Google Scholar
• Liu H, Wu Z, Ma Z, Wu B. (2014b). Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes. Biopharm Drug Dispos 35:513–24
   PubMed Web of Science ®Google Scholar
• Liu W, Feng Q, Li Y, et al. (2012). Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. Toxicol Appl Pharmacol 65:316–24
   Google Scholar
• Liu W, Liu H, Sun H, et al. (2014c). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica 44:455–64
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu M. (2002). Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos 30:370–7
   PubMed Web of Science ®Google Scholar
• Liu Y, She M, Wu Z, Dai R. (2011). The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors. J Enzyme Inhib Med Chem 26:386–93
   PubMed Web of Science ®Google Scholar
• Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC. (2010). Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38:2232–8
   PubMed Web of Science ®Google Scholar
• Nagar S, Blanchard RL. (2006). Pharmacogenetics of UGT1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393–409
   PubMed Web of Science ®Google Scholar
• Oleson L, Court MH. (2008). Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175–82
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329:15–19
   PubMed Web of Science ®Google Scholar
• Polasek TM, Lin FPY, Miners JO, Doogue MP. (2011). Perpetrators of pharmacokinetic drug–drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 71:727–36
   PubMed Web of Science ®Google Scholar
• Quan E, Wang H, Dong D, et al. (2015). Characterization of chrysin glucuronidation in UGT1A1-overexpressing HeLa cells: elucidating the transporters responsible for efflux of glucuronide. Drug Metab Dispos 43:433–43
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya A, Ouzzine M, Fournel-Gigleux S, Magdalou J. (2005). Structure of UDP-glucuronosyltransferases in membranes. Methods Enzymol 400:116–47
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. (2013). The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121–32
   PubMed Web of Science ®Google Scholar
• Sahai J, Gallicano K, Pakuts A, Cameron DW. (1994). Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 169:1103–7
   PubMed Web of Science ®Google Scholar
• Sato Y, Nagata M, Kawamura A, et al. (2012). Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities. Xenobiotica 42:823–9
   PubMed Web of Science ®Google Scholar
• Sun H, Wang H, Liu H, et al. (2014). Glucuronidation of capsaicin by liver microsomes and expressed UGT enzymes: reaction kinetics, contribution of individual enzymes and marked species differences. Expert Opin Drug Metab Toxicol 10:1325–36
   PubMed Web of Science ®Google Scholar
• Walters WP, Green J, Weiss JR, Murcko MA. (2011). What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 54:6405–16
   PubMed Web of Science ®Google Scholar
• Wu B, Kulkarni K, Basu S, et al. (2011a). First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci 100:3655–81
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang S, Hu M. (2011b). Evaluation of 3,3′,4′-trihydroxyflavone and 3,6,4′-trihydroxyflavone (4′-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Mol Pharm 8:2379–89
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang D, Cui D, et al. (2007). Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 35:2270–80
   PubMed Web of Science ®Google Scholar